Skip to main content

Table 2 Distribution of antibiotic treatment according to acquisition group*

From: Pseudomonas aeruginosa acquisition on an intensive care unit: relationship between antibiotic selective pressure and patients' environment

  P. aeruginosa acquisition n= 20 (%) No P. aeruginosa acquisition n= 106 (%) Total n= 126 (%)
Antibiotics active against P. aeruginosa 10 (50) 57 (54) 67 (53)
Aminosides 6 (30) 17 (16) 23 (18)
Ureido/carboxypenicillins 5 (25) 19 (18) 24 (19)
   Piperacillin-tazobactam 5 (25) 12 (11) 17 (13)
   Ticarcillin-clavulanic acid 0 (0) 7 (7) 7 (6)
Antipseudomonal cephalosporins 3 (15) 13 (12) 16 (13)
   Ceftazidime 3 (15) 6 (6) 9 (7)
   Cefepime 0 (0) 7 (7) 7 (6)
Carbapenems 4 (20) 12 (11) 16 (13)
Fluoroquinolones 7 (35) 33 (31) 40 (32)
Others 1 (5) 3 (3) 4 (3)
   Fosfomycin 0 (0) 2 (2) 2 (2)
   Colomycin 1 (5) 1 (1) 2 (2)
Antibiotics not active against P. aeruginosa 14 (70) 85 (80) 99 (79)
Glycopeptides 5 (25) 30 (28) 35 (28)
Non-antipseudomonal penicillins 4 (20) 43 (41) 47 (37)
   Penicillin G 0 (0) 1 (1) 1 (1)
   Penicillin M 0 (0) 2 (2) 2 (2)
   Amoxicillin 1 (5) 3 (3) 4 (3)
   Amoxicillin-clavulanic acid 3 (15) 37 (35) 40 (32)
Non-antipseudomonal cephalosporins (cefotaxim; cefuroxim; ceftriaxon) 10 (50) 23 (22) 33 (26)
Macrolides 5 (25) 12 (11) 17 (13)
Other 2 (10) 18 (17) 20 (16)
   Pristinamycin 0 (0) 3 (3) 3 (2)
   Metronidazole 0 (0) 10 (9) 10 (8)
   Cotrimoxazole 1 (5) 1 (1) 2 (2)
   Rifampicin 1 (5) 4 (4) 5 (4)
  1. * The data represent the number of patients who received at least one day of antibiotic of each class (percentage of patients in each group).